Rockefeller Capital Management L.P. Sells 6,164 Shares of NeoGenomics, Inc. $NEO

Rockefeller Capital Management L.P. trimmed its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 12.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 44,471 shares of the medical research company’s stock after selling 6,164 shares during the period. Rockefeller Capital Management L.P.’s holdings in NeoGenomics were worth $325,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Light Asset Management LLC grew its holdings in NeoGenomics by 90.8% during the first quarter. First Light Asset Management LLC now owns 6,042,822 shares of the medical research company’s stock valued at $57,346,000 after purchasing an additional 2,875,237 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of NeoGenomics by 14.7% during the 1st quarter. American Century Companies Inc. now owns 3,319,602 shares of the medical research company’s stock worth $31,503,000 after buying an additional 426,341 shares during the period. Geode Capital Management LLC grew its stake in NeoGenomics by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 3,156,621 shares of the medical research company’s stock valued at $23,078,000 after buying an additional 26,224 shares during the last quarter. Jennison Associates LLC grew its stake in NeoGenomics by 8.9% in the 2nd quarter. Jennison Associates LLC now owns 1,663,905 shares of the medical research company’s stock valued at $12,163,000 after buying an additional 136,638 shares during the last quarter. Finally, Samjo Management LLC bought a new position in NeoGenomics in the 1st quarter worth $5,970,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $12.13 on Friday. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -13.78 and a beta of 1.67. NeoGenomics, Inc. has a one year low of $4.72 and a one year high of $19.11. The business has a fifty day simple moving average of $9.82 and a 200 day simple moving average of $8.06. The company has a current ratio of 3.91, a quick ratio of 3.58 and a debt-to-equity ratio of 0.41.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.01. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The firm had revenue of $187.80 million for the quarter, compared to analyst estimates of $183.85 million. During the same quarter in the previous year, the firm posted $0.05 EPS. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Sell-side analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Piper Sandler set a $11.00 price target on shares of NeoGenomics and gave the company an “overweight” rating in a report on Monday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday. TD Cowen raised their target price on NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, September 12th. Leerink Partners set a $14.00 price target on NeoGenomics in a research report on Tuesday, October 28th. Finally, Stephens upped their price target on NeoGenomics from $6.50 to $11.00 and gave the stock an “overweight” rating in a report on Tuesday, September 2nd. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $13.11.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.